World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01003613
Date of registration: 28/10/2009
Primary sponsor: Gildasio Castello de Almeida Junior
Public title: Evaluation of Tranilast to Treat Pterygium Before Excision TPS
Scientific title: Evaluation of Tranilast as Adjunctive Therapy Before Primary Pterygium Excision Compared With Conjunctival Autograft
Date of first enrolment: February 2009
Target sample size: 32
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01003613
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment  
Countries of recruitment
Brazil
Contacts
Name:   Acacio AS Lima Filho, MD
Address: 
Telephone:
Email:
Affiliation:  Federal University of São Paulo
Name:   Reinaldo Azoubel, Prof Dr
Address: 
Telephone:
Email:
Affiliation:  Prof Dr
Name:   Gildasio C Almeida Jr, Prof Dr
Address: 
Telephone:
Email:
Affiliation:  Sao Jose do Rio Preto University
Name:   Vinicius Tadeu NS Nascimento, Student
Address: 
Telephone:
Email:
Affiliation:  Sao Jose do Rio Preto University
Name:   Sidney JF Sousa, Prof Dr
Address: 
Telephone:
Email:
Affiliation:  USP - Ribeirão Preto
Key inclusion & exclusion criteria

Inclusion Criteria:

- Primary pterygium

Exclusion Criteria:

- Keratoconjunctivitis sicca

- Sjögren disease

- Vernal keratoconjunctivitis

- Acne rosacea

- Neurotrophic keratopathy

- Severe dysfunction of the meibomius glands

- Use of any immunosuppressive drug, through systemic and topical route

- Aged under 18 years of age and vulnerable groups

- Glaucoma and use of ocular hipotensor



Age minimum: 18 Years
Age maximum: 65 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Pterygium
Intervention(s)
Drug: Tranilast, and Tissucol
Other: Beriplast P
Primary Outcome(s)
Recurrence rate at months six and twelve months Immunohistochemical and cell morphology analysis at the end of study, 12 months [Time Frame: 6 and 12 months]
Secondary Outcome(s)
Patient discomfort at day one, six and twelve months Safety of Tranilast [Time Frame: one day, 6 and 12 months]
Secondary ID(s)
3049/2009
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Hospital de Base
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history